Medications

Mounjaro's Generic Name: Everything to Know About Tirzepatide

GLP-1 Companion · 7 min read

Mounjaro's Generic Name: Tirzepatide

The generic (non-brand) name for Mounjaro is tirzepatide. Brand names and generic names follow a consistent pattern in pharmacy: the brand name is the trademarked product name given by the manufacturer (Mounjaro, owned by Eli Lilly), while the generic name is the internationally recognized chemical name used across all regulatory agencies, medical literature, and formularies.

Tirzepatide is also sold under the brand name Zepbound — the same molecule, same doses, but FDA-approved specifically for chronic weight management in adults with obesity or overweight with a weight-related condition. Mounjaro carries the FDA approval for type 2 diabetes management. This dual-brand situation, where the identical drug is marketed under two names for two different indications, is common with GLP-1 class medications (compare Ozempic vs. Wegovy, which are both semaglutide).

What Class of Drug Is Tirzepatide?

Tirzepatide belongs to a new drug class called dual GIP/GLP-1 receptor agonists, sometimes called "twincretins." This distinguishes it from older GLP-1 receptor agonists like semaglutide (Ozempic/Wegovy) and liraglutide (Saxenda/Victoza), which activate only the GLP-1 receptor.

GIP stands for glucose-dependent insulinotropic polypeptide — a gut hormone that works alongside GLP-1 to regulate insulin secretion, blood sugar, and body weight. By activating both the GIP and GLP-1 receptors simultaneously, tirzepatide produces additive effects on appetite suppression, slowing of stomach emptying, and insulin sensitization that exceed what GLP-1 activation alone achieves.

How Tirzepatide Works

After injection (tirzepatide is a once-weekly subcutaneous injection), tirzepatide binds to both GIP and GLP-1 receptors in the brain, gut, pancreas, and adipose tissue. Key mechanisms include:

• Appetite suppression via hypothalamic GLP-1 receptors — reducing hunger signals and food noise
• Slowed gastric emptying — food stays in the stomach longer, prolonging satiety signals
• Enhanced insulin secretion in response to meals — improving blood sugar control in T2D
• Improved insulin sensitivity in fat and liver tissue via GIP receptor activity
• Direct effects on fat cells that may enhance fat breakdown independent of caloric reduction

The dual-receptor mechanism is believed to explain why tirzepatide produces greater weight loss than semaglutide in head-to-head comparisons. The SURMOUNT-5 trial, published in 2024, compared tirzepatide directly to semaglutide for weight management and found tirzepatide produced approximately 47% more weight loss on average.

Tirzepatide Doses: Mounjaro and Zepbound

Both Mounjaro and Zepbound use the same dose escalation schedule. Tirzepatide is started at a low dose and gradually increased to reduce gastrointestinal side effects:

• 2.5 mg once weekly — starting dose (4 weeks)
• 5 mg once weekly — step-up at week 4 (minimum 4 weeks)
• 7.5 mg once weekly — optional step-up
• 10 mg once weekly — optional step-up
• 12.5 mg once weekly — optional step-up
• 15 mg once weekly — maximum dose

Not every patient needs to reach the maximum dose. The treating provider will typically increase the dose every 4 weeks as tolerated, stopping at the dose that achieves the desired clinical outcome with acceptable side effects. The 2.5 mg starting dose is specifically designed to minimize early nausea — which is why many patients find the first four weeks more comfortable than they expected.

Tirzepatide vs. Semaglutide: Key Differences

The most common comparison people make is between tirzepatide (Mounjaro/Zepbound) and semaglutide (Ozempic/Wegovy). Here are the key distinctions:

• Mechanism: Tirzepatide activates both GIP and GLP-1 receptors; semaglutide activates GLP-1 only
• Weight loss: Tirzepatide produces ~20–22% body weight reduction at 15 mg vs. ~15% with semaglutide 2.4 mg in obesity trials
• Blood sugar control: Both are highly effective for T2D; tirzepatide may have a slight edge in A1C reduction
• Injection frequency: Both are once-weekly injections
• Side effect profile: Very similar — both cause nausea, constipation, and GI side effects during titration
• Cost: Both are expensive without insurance, typically $900–$1,200/month list price in the US

Is There a Generic Version of Tirzepatide Available?

As of mid-2026, there is no FDA-approved generic version of tirzepatide available on the US market. Brand-name biologic and peptide drugs like tirzepatide are protected by multiple layers of patents — covering the molecule, its formulation, the delivery device, and manufacturing processes. Eli Lilly's core composition-of-matter patent on tirzepatide does not expire until the mid-2030s in the United States.

When patents do expire, the FDA regulatory pathway for complex peptide drugs produces "biosimilar" or "follow-on" products rather than simple generics (the kind available for small-molecule drugs). These biosimilar or generic peptide versions must demonstrate bioequivalence to the original before approval. This pathway exists but takes years to execute after patent expiry.

Compounded tirzepatide was briefly available through 503B outsourcing facilities while Mounjaro was classified as in shortage. The FDA removed tirzepatide from the shortage list in late 2025, and large-scale compounding of commercially available tirzepatide doses by outsourcing facilities is no longer legally permitted under FDA guidance. Some individual 503A compounding pharmacies may still prepare it for specific patients, but this remains in a regulatory gray area.

How to Pronounce Tirzepatide

Tirzepatide is pronounced: tir-ZEP-a-tide. Breaking it down: "tir" (rhymes with "tier"), "ZEP" (like "zap" with an "e"), "a" (schwa sound), "tide" (like ocean tide). The emphasis falls on the second syllable. You will also see it abbreviated as TZP in medical literature.

Who Should Not Take Tirzepatide?

Tirzepatide (Mounjaro/Zepbound) carries contraindications similar to other GLP-1 medications. It should not be used by people with:

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Known hypersensitivity to tirzepatide or any component of the formulation
• Type 1 diabetes (not indicated and may increase DKA risk)
• Pregnancy or planned pregnancy (weight loss during pregnancy not recommended)

Patients with a history of pancreatitis, severe gastrointestinal disease, or diabetic gastroparesis should discuss the risks with their provider before starting tirzepatide, as these conditions may be exacerbated.

Bottom Line

Mounjaro's generic name is tirzepatide — a dual GIP/GLP-1 receptor agonist and currently one of the most effective obesity and T2D medications available. It is identical to Zepbound, which carries the obesity indication. No true generic or biosimilar version is available in the US as of 2026, and none is expected before the mid-2030s at the earliest. For patients seeking more affordable access, manufacturer patient assistance programs (Lilly Cares) and Medicare/Medicaid coverage pathways are the primary options.

Sources

• SURMOUNT-5: Tirzepatide vs. semaglutide head-to-head trial (NEJM 2024)
• FDA Prescribing Information: Mounjaro (tirzepatide) injection
• FDA Prescribing Information: Zepbound (tirzepatide) injection